Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2023-08-23 00:00:00 ET · period of report 2023-08-21 · accession 0001209191-23-047103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-23 | 2023-08-21 | VERA | Curley Joanne | Chief Development Off | S - Sale | $16.66 | -1,490 | 27.0K | -5% | -$24.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-08-21 | S | D | 1,490 | $16.66 | 26,962 | D | — | — | (F2) The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F3) Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares. |